IL222751A0 - Pharmaceutical compositions and methods of making same - Google Patents
Pharmaceutical compositions and methods of making sameInfo
- Publication number
- IL222751A0 IL222751A0 IL222751A IL22275112A IL222751A0 IL 222751 A0 IL222751 A0 IL 222751A0 IL 222751 A IL222751 A IL 222751A IL 22275112 A IL22275112 A IL 22275112A IL 222751 A0 IL222751 A0 IL 222751A0
- Authority
- IL
- Israel
- Prior art keywords
- methods
- pharmaceutical compositions
- making same
- making
- same
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Inorganic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33171510P | 2010-05-05 | 2010-05-05 | |
| PCT/US2011/035363 WO2011140343A1 (en) | 2010-05-05 | 2011-05-05 | Pharmaceutical compositions and methods of making same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL222751A0 true IL222751A0 (en) | 2012-12-31 |
Family
ID=44851507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL222751A IL222751A0 (en) | 2010-05-05 | 2012-10-29 | Pharmaceutical compositions and methods of making same |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US20120028918A1 (https=) |
| EP (1) | EP2566331B1 (https=) |
| JP (1) | JP5835717B2 (https=) |
| KR (1) | KR20130071434A (https=) |
| CN (1) | CN102970871A (https=) |
| AR (1) | AR081364A1 (https=) |
| AU (1) | AU2011247995B2 (https=) |
| BR (1) | BR112012028291A2 (https=) |
| CA (1) | CA2798386A1 (https=) |
| CL (1) | CL2012003075A1 (https=) |
| CO (1) | CO6640262A2 (https=) |
| CR (1) | CR20120556A (https=) |
| DO (1) | DOP2012000281A (https=) |
| EA (1) | EA201291168A1 (https=) |
| ES (1) | ES2519615T3 (https=) |
| IL (1) | IL222751A0 (https=) |
| MA (1) | MA34286B1 (https=) |
| MX (1) | MX2012012837A (https=) |
| NZ (1) | NZ603411A (https=) |
| PE (1) | PE20130217A1 (https=) |
| PH (1) | PH12012502159A1 (https=) |
| SG (1) | SG185087A1 (https=) |
| TW (1) | TW201206908A (https=) |
| UY (1) | UY33367A (https=) |
| WO (1) | WO2011140343A1 (https=) |
| ZA (1) | ZA201208265B (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070020299A1 (en) | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
| ES2493641T3 (es) * | 2007-06-28 | 2014-09-12 | Cydex Pharmaceuticals, Inc. | Administración nasal de soluciones acuosas de corticosteroides |
| US12370352B2 (en) | 2007-06-28 | 2025-07-29 | Cydex Pharmaceuticals, Inc. | Nasal and ophthalmic delivery of aqueous corticosteroid solutions |
| US8623395B2 (en) | 2010-01-29 | 2014-01-07 | Forsight Vision4, Inc. | Implantable therapeutic device |
| WO2013022801A1 (en) | 2011-08-05 | 2013-02-14 | Forsight Vision4, Inc. | Small molecule delivery with implantable therapeutic device |
| AR081364A1 (es) * | 2010-05-05 | 2012-08-29 | Glaxo Wellcome Mfg Pte Ltd | Composiciones farmaceuticas de pazopanib y metodos para su elaboracion |
| EP3861969A1 (en) | 2010-08-05 | 2021-08-11 | ForSight Vision4, Inc. | Injector apparatus for drug delivery |
| WO2012068549A2 (en) | 2010-11-19 | 2012-05-24 | Forsight Vision4, Inc. | Therapeutic agent formulations for implanted devices |
| PT2755600T (pt) | 2011-09-16 | 2021-04-19 | Forsight Vision4 Inc | Aparelhos de troca de fluidos |
| AU2013221298A1 (en) * | 2012-02-17 | 2014-08-28 | Pharmacyclics Llc | Combinations of histone deacetylase inhibitor and pazopanib and uses thereof |
| CN110062479A (zh) * | 2012-03-08 | 2019-07-26 | 三星电子株式会社 | 用于控制无线通信系统中的服务的方法 |
| WO2014152959A1 (en) * | 2013-03-14 | 2014-09-25 | Forsight Vision4, Inc. | Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant |
| CN105246438B (zh) | 2013-03-28 | 2018-01-26 | 弗赛特影像4股份有限公司 | 用于输送治疗物质的眼科植入物 |
| ES2813877T3 (es) | 2013-08-28 | 2021-03-25 | Crown Bioscience Inc Taicang | Distintivos de expresión génica predictivos de la respuesta de un sujeto a un inhibidor multicinasa y métodos de uso de los mismos |
| RU2017105844A (ru) * | 2014-08-08 | 2018-09-11 | Форсайт Вижн4, Инк. | Стабильные и растворимые составы ингибиторов рецепторных тирозинкиназ и способы их получения |
| CN110478119B (zh) | 2014-11-10 | 2022-04-15 | 弗赛特影像4股份有限公司 | 可膨胀药物递送装置和使用方法 |
| JP6818264B2 (ja) | 2014-12-25 | 2021-01-20 | 国立大学法人京都大学 | 高密度リポタンパク質およびその細胞親和性ペプチドを融合した高密度リポタンパク質の点眼による後眼部薬物デリバリー |
| CN113017981B (zh) | 2016-04-05 | 2023-07-25 | 弗赛特影像4股份有限公司 | 药物递送装置 |
| WO2018192416A1 (en) * | 2017-04-17 | 2018-10-25 | National Institute Of Biological Sciences, Beijing | Treating Male Senescence |
| WO2019028104A1 (en) * | 2017-08-02 | 2019-02-07 | Alphala Co., Ltd. | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME |
| EP4249069B1 (en) * | 2018-06-07 | 2025-11-19 | Pfizer Inc. | Aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea |
| CN113350351A (zh) * | 2020-03-13 | 2021-09-07 | 青晓制药公司 | 帕唑帕尼的应用、药物组合物、注射液及制备方法和应用 |
| USD1033637S1 (en) | 2022-01-24 | 2024-07-02 | Forsight Vision4, Inc. | Fluid exchange device |
| US20240050429A1 (en) * | 2022-08-10 | 2024-02-15 | Qx Therapeutics, Inc. | Pazopanib pharmaceutical composition, injection and preparation method and use thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8904296D0 (sv) * | 1989-12-21 | 1989-12-21 | Pharmacia Ab | Transdermal system |
| US7893040B2 (en) * | 2005-07-22 | 2011-02-22 | Oculis Ehf | Cyclodextrin nanotechnology for ophthalmic drug delivery |
| EA016227B1 (ru) * | 2005-11-29 | 2012-03-30 | Смитклайн Бичем Корпорейшн | Способ лечения офтальмологических неоваскулярных расстройств |
| AR059066A1 (es) * | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
| MX2008013405A (es) * | 2006-04-18 | 2009-03-09 | Ekr Therapeutics Inc | Composiciones farmaceuticas premezcladas listas para uso. |
| ES2830024T3 (es) * | 2007-10-19 | 2021-06-02 | Novartis Ag | Composiciones y métodos para el tratamiento del edema macular |
| US8987280B2 (en) * | 2008-01-30 | 2015-03-24 | Genentech, Inc. | Pyrazolopyrimidine PI3K inhibitor compounds and methods of use |
| AU2010273254A1 (en) * | 2009-07-16 | 2012-02-02 | Glaxo Wellcome Manufacturing Pte Ltd | Treatment method |
| US20120232102A1 (en) * | 2009-09-30 | 2012-09-13 | Chun-Fang Xu | Methods Of Administration And Treatment |
| UY33164A (es) * | 2010-01-06 | 2011-08-31 | Glaxo Wellcome Mfg Pte Ltd | Metodo de tratamiento |
| US20130023550A1 (en) * | 2010-05-05 | 2013-01-24 | Glaxo Wellcome Manufacturing Pte, Ltd | Pharmaceutical compositions and methods of making same |
| AR081364A1 (es) * | 2010-05-05 | 2012-08-29 | Glaxo Wellcome Mfg Pte Ltd | Composiciones farmaceuticas de pazopanib y metodos para su elaboracion |
-
2011
- 2011-05-03 AR ARP110101514A patent/AR081364A1/es unknown
- 2011-05-03 UY UY0001033367A patent/UY33367A/es unknown
- 2011-05-03 TW TW100115488A patent/TW201206908A/zh unknown
- 2011-05-05 PH PH1/2012/502159A patent/PH12012502159A1/en unknown
- 2011-05-05 CN CN2011800333447A patent/CN102970871A/zh active Pending
- 2011-05-05 MX MX2012012837A patent/MX2012012837A/es active IP Right Grant
- 2011-05-05 KR KR1020127031739A patent/KR20130071434A/ko not_active Withdrawn
- 2011-05-05 CA CA2798386A patent/CA2798386A1/en not_active Abandoned
- 2011-05-05 NZ NZ603411A patent/NZ603411A/en not_active IP Right Cessation
- 2011-05-05 JP JP2013509268A patent/JP5835717B2/ja not_active Expired - Fee Related
- 2011-05-05 AU AU2011247995A patent/AU2011247995B2/en not_active Ceased
- 2011-05-05 WO PCT/US2011/035363 patent/WO2011140343A1/en not_active Ceased
- 2011-05-05 ES ES11778348.0T patent/ES2519615T3/es active Active
- 2011-05-05 MA MA35417A patent/MA34286B1/fr unknown
- 2011-05-05 US US13/133,030 patent/US20120028918A1/en not_active Abandoned
- 2011-05-05 US US13/101,689 patent/US20110281901A1/en not_active Abandoned
- 2011-05-05 PE PE2012002115A patent/PE20130217A1/es not_active Application Discontinuation
- 2011-05-05 EA EA201291168A patent/EA201291168A1/ru unknown
- 2011-05-05 BR BR112012028291A patent/BR112012028291A2/pt not_active IP Right Cessation
- 2011-05-05 EP EP11778348.0A patent/EP2566331B1/en active Active
- 2011-05-05 SG SG2012079968A patent/SG185087A1/en unknown
-
2012
- 2012-10-29 IL IL222751A patent/IL222751A0/en unknown
- 2012-10-31 CL CL2012003075A patent/CL2012003075A1/es unknown
- 2012-11-01 CR CR20120556A patent/CR20120556A/es unknown
- 2012-11-02 DO DO2012000281A patent/DOP2012000281A/es unknown
- 2012-11-02 ZA ZA2012/08265A patent/ZA201208265B/en unknown
- 2012-12-05 CO CO12221016A patent/CO6640262A2/es not_active Application Discontinuation
-
2015
- 2015-05-06 US US14/705,298 patent/US20150231265A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20130071434A (ko) | 2013-06-28 |
| TW201206908A (en) | 2012-02-16 |
| PH12012502159A1 (en) | 2013-02-04 |
| JP2013525501A (ja) | 2013-06-20 |
| AU2011247995A1 (en) | 2012-12-13 |
| DOP2012000281A (es) | 2013-05-31 |
| PE20130217A1 (es) | 2013-03-21 |
| CN102970871A (zh) | 2013-03-13 |
| JP5835717B2 (ja) | 2015-12-24 |
| SG185087A1 (en) | 2012-12-28 |
| AR081364A1 (es) | 2012-08-29 |
| US20150231265A1 (en) | 2015-08-20 |
| MA34286B1 (fr) | 2013-06-01 |
| CR20120556A (es) | 2013-02-20 |
| UY33367A (es) | 2011-10-31 |
| US20120028918A1 (en) | 2012-02-02 |
| EP2566331B1 (en) | 2014-09-03 |
| EP2566331A1 (en) | 2013-03-13 |
| WO2011140343A1 (en) | 2011-11-10 |
| ZA201208265B (en) | 2013-07-31 |
| CL2012003075A1 (es) | 2013-03-08 |
| EP2566331A4 (en) | 2013-09-18 |
| HK1175947A1 (en) | 2013-07-19 |
| CA2798386A1 (en) | 2011-11-10 |
| BR112012028291A2 (pt) | 2015-09-15 |
| AU2011247995B2 (en) | 2014-07-31 |
| EA201291168A1 (ru) | 2013-06-28 |
| MX2012012837A (es) | 2013-01-24 |
| CO6640262A2 (es) | 2013-03-22 |
| NZ603411A (en) | 2014-10-31 |
| US20110281901A1 (en) | 2011-11-17 |
| ES2519615T3 (es) | 2014-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201208265B (en) | Pharmaceutical compositions and methods of making same | |
| IL265327A (en) | xten duo preparations and methods for their production | |
| IL253870B (en) | Certain amino-pyrimidines and pharmaceutical preparations containing them | |
| IL250824B (en) | Certain amino-pyrimidines, their assemblies, and methods of using them | |
| SG10201605794PA (en) | Stable Pharmaceutical Composition And Methods Of Using Same | |
| EP2521553A4 (en) | METHODS AND COMPOSITIONS FOR THE DEVELOPMENT OF TARGETED MEDICAMENTS | |
| IL222291A0 (en) | Compositions and methods of synthesis of pyridinoylpiperidine | |
| EP2593571A4 (en) | SWEETENER COMPOSITIONS AND METHODS OF PRODUCING THE SAME | |
| GB2478849A8 (en) | Improved pharmaceutical compositions and methods of delivery | |
| HUE056835T2 (hu) | Karbetocint tartalmazó gyógyászati készítmény | |
| GB201302653D0 (en) | Pharmaceutical compositions and methods of treatment | |
| IL220715A0 (en) | Nutritive compositions and methods of using same | |
| EP2566485A4 (en) | IMMUNOSTIMULATORY COMPOSITIONS AND METHODS OF USE THEREOF | |
| SG10201604468QA (en) | Shk-based pharmaceutical compositions and methods of manufacturing and using the same | |
| IL219018A (en) | Radzolid Pharmaceuticals and Uses | |
| GB201002278D0 (en) | composition and method of preparation | |
| HK1177747A (en) | Hsa-related compositions and methods of use | |
| HK1162316A (en) | Improved pharmaceutical compositions and methods of delivery | |
| GB201003741D0 (en) | Methods and therapeutic compositions |